Esquizofrenia
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe
The Lancet Psychiatry Fecha de publicación: 1 de enero de 2022 Autores: Dragana Bugarski-Kirola, MD , Prof Celso Arango, MD, Prof...
Medicina personalizada contra la esquizofrenia para mejorar tratamientos
El Centro de Investigación Biomédica en Red, a través del área de Salud Mental (Cibersam) ha obtenido una ayuda de 1.192.431,90 euros de...
Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study
Lancet Psychiatry Fecha de publicación: 1 de diciembre de 2021 Autores: Hannah J Jones, PhD , Maria Carolina Borges, PhD, Rebecca...
COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study
The Lancet Psychiatry Fecha de publicación: 5 de agosto de 2021 Autores: Dana Tzur Bitan, PhD ,Khalaf Kridin, PhD, Prof Arnon...
Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs
American Journal of Psychiatry Fecha de publicación: 14 de julio de 2021 Autores: Mark Weiser, M.D., John M. Davis, M.D., Clayton H. Brown, Ph.D., Eric P....
Lo más popular
Uncovering the realities of delusional experience in schizophrenia: a qualitative phenomen... 
Schizophrenia risk alleles and neurodevelopmental outcomes in childhood: a population-base... 
La esquizofrenia disminuye la esperanza de vida en 15 años 
Sleep Abnormalities in Schizophrenia: State of the Art and Next Steps 
Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mend... 
Accelerated Gray and White Matter Deterioration With Age in Schizophrenia 
Years of potential life lost and life expectancy in schizophrenia: a systematic review and...